Medtronic Launches Telescope(TM) Guide Extension Catheter to Support Complex Coronary Cases
May 16 2019 - 09:30AM
FDA Cleared and CE
Marked, Telescope Enters Global Market with Design Innovations to
Enable Smooth Delivery of Coronary Stents and Balloons
DUBLIN - May 16, 2019 -
Medtronic plc (NYSE:MDT), a global leader in percutaneous coronary
intervention (PCI) innovation, today announced its entrance into
the guide extension catheter market with the global launch of the
Telescope(TM) Guide Extension Catheter, a newly designed catheter
used to provide additional backup support and access to distal
lesions. Guide extension catheters help deliver coronary stents,
balloons and other interventional devices during angioplasty
procedures that help to restore blood flow through the coronary and
peripheral arteries.
Developed alongside interventional cardiologists,
many of whom are increasingly challenged with complex cases - such
as patients with tortuous anatomies, calcified vessels, and distal
lesions - the Telescope guide extension catheter provides operators
with superior deliverability1 and is
designed to enable smooth delivery of interventional devices in
more challenging cases.
"It is not an exaggeration to say that guide
extension technologies have greatly impacted the ability to deliver
devices to the distal coronary vasculature, especially for cases
where traditional guide support may be limited," said Ajay Kirtane,
M.D., S.M., director of the NewYork-Presbyterian Hospital/Columbia
University Cardiac Catheterization Laboratories. "In this light,
the Telescope - a guide extension catheter with specific design
optimizations aiming to stably deliver devices through tortuous
anatomy - is a welcome addition to the interventional toolbox."
The Telescope guide extension catheter combines a
solid, round pushwire with a coil-reinforced hydrophilic-coated
distal segment to help physicians reach challenging lesions with
improved pushability and deliverability.2 Telescope
also features a flexible TruFlex(TM) soft polymer tip, which is
designed to responsively bend and deflect during use. In addition,
once Telescope is in position near the target lesion, SmoothPass
technology helps to smoothly channel stents, balloons, and other
interventional devices into place.
"Before bringing this important technology to
market, we collaborated with more than 700 interventional
cardiologists to ensure Telescope was addressing unmet needs in
complex PCI," said Dave Moeller, vice president and general manager
of the Coronary and Renal Denervation business, which is part of
the Cardiac and Vascular Group at Medtronic. "We will continue to
make investments in cutting edge interventional technologies,
clinical evidence expansion, and robust physician training
programs, which we believe will make a meaningful difference for
physicians and their patients."
In addition to the Telescope guide extension
catheter, Medtronic's market-leading coronary portfolio includes
the latest-generation Resolute Onyx(TM) Drug-Eluting Stent (DES),
the Euphora(TM) line of pre- and post-dilatation balloon catheters,
and a full suite of catheters including the DxTerity(TM) TRA
Diagnostic Catheter and market-leading Launcher® Guide Catheter,
all of which are commercially available in the U.S., as well as
throughout Europe.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is among the world's largest medical technology, services
and solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 86,000 people worldwide, serving physicians,
hospitals and patients in more than 150 countries. The company is
focused on collaborating with stakeholders around the world to take
healthcare Further, Together.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
- Deliverability bench testing: Telescope(TM) GEC 6
F vs. GuideLiner(TM)* V3 5.5 F/6 F vs. Guidezilla(TM)* II
6F Bench test data. Bench test data may not be indicative of
clinical performance.
- Deliverability bench testing: Telescope(TM) GEC 6
F vs. GuideLiner(TM)* V3 5.5 F/6 F vs. Guidezilla(TM)* II 6
F. Pushability bench testing: Telescope(TM) GEC 6 F vs.
GuideLiner(TM)* V3 6 F vs. Guidezilla(TM)* II 6 F. Bench test data
may not be indicative of clinical performance.
Contacts:
Joey Lomicky
Public Relations
+1-763-526-2494
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
Medtronic (NYSE:MDT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2023 to Mar 2024